Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Unknown 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 171Thoracic 52Head & Neck 46Breast 40Gynecologic 23Sarcoma 14Lymphoid 13Other solid neoplasm 11Dermatologic 7CNS 6Genitourinary 5Other hematologic neoplasm 4Tumor-Agnostic 3Endocrine 2Other neoplasm 1

Conditions

Urinary Bladder Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Unresectable Gallbladder Cancer 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × camrelizumab × Genitourinary × Clear all
NCT04706598 2024-07-12

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Fudan University

Phase 1/2 Active not recruiting
25 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT06423170 2024-05-21

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Recruiting
37 enrolled
GastrointestinalGenitourinary

Unresectable Gallbladder Cancer

NCT05564897 2022-10-04

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

Zhejiang Cancer Hospital

Phase 2 Unknown
25 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03987698 2020-07-07

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
90 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡